New Content  edit

Loading the player...
CHEST 2014: Highlights of AMBITION and COMPASS II
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Dr. Vallerie McLaughlin of University of Michigan discusses the AMBITION (Ambrisentan and Tadalafil combination therapy) and COMPASS II (Bosentan added to Sildenafil) studies, and implications for treatment of PAH. Recorded at CHEST 2014, held October 25-30 in Austin, TX